Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$16M
- −92.6% YoY
- EPS (diluted)
- −$1.20
- −62.2% YoY
Source: XBRL data from the PALVELLA THERAPEUTICS, INC. (PVLA) Q1 2026 10-Q on SEC EDGAR. USD.
PALVELLA THERAPEUTICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to risk factors from the 2025 Form 10-K
- Newly added risk factors: none disclosed
- Regulatory, legal, and compliance risks: carried-forward risks unchanged from the 2025 Form 10-K
- Operational, competitive, and market risks: carried-forward risks unchanged from the 2025 Form 10-K
- Financial risks: carried-forward risks unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PALVELLA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.